Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Identifying and treating patients with suboptimal responses.

Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H.

Neurology. 2004 Dec 28;63(12 Suppl 6):S33-40. Review.

PMID:
15623669
2.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
3.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
4.

Review of mitoxantrone in the treatment of multiple sclerosis.

Jeffery DR, Herndon R.

Neurology. 2004 Dec 28;63(12 Suppl 6):S19-24. Review.

PMID:
15623665
5.

[Mitoxantrone for the treatment of patients with multiple sclerosis].

Komori M, Kondo T, Tanaka M.

Brain Nerve. 2009 May;61(5):575-80. Review. Japanese.

PMID:
19514518
6.

The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

Murray TJ.

Expert Opin Drug Saf. 2006 Mar;5(2):265-74. Review.

PMID:
16503747
7.

Mitoxantrone for multiple sclerosis in clinical practice.

Rizvi SA, Zwibel H, Fox EJ.

Neurology. 2004 Dec 28;63(12 Suppl 6):S25-7. Review.

PMID:
15623666
8.
9.

Rationale for the use of mitoxantrone in multiple sclerosis.

Edan G, Morrissey S, Le Page E.

J Neurol Sci. 2004 Aug 15;223(1):35-9. Review.

PMID:
15261558
10.

A practical approach to immunomodulatory therapy for multiple sclerosis.

Burks JS.

Phys Med Rehabil Clin N Am. 2005 May;16(2):449-66, ix. Review.

PMID:
15893681
11.

[Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].

Ory S, Debouverie M, Le Page E, Pelletier J, Malikova I, Gout O, Roullet E, Vermersch P, Edan G.

Rev Neurol (Paris). 2008 Dec;164(12):1028-34. doi: 10.1016/j.neurol.2008.04.008. Epub 2008 Jun 9. French.

PMID:
18808781
12.

Clinically isolated syndromes: predicting and delaying multiple sclerosis.

Thrower BW.

Neurology. 2007 Jun 12;68(24 Suppl 4):S12-5. Review.

PMID:
17562845
13.

Treatment optimisation in multiple sclerosis.

Zaffaroni M.

Neurol Sci. 2005 Dec;26 Suppl 4:S187-92. Review.

PMID:
16388356
14.

Predicting and preventing the future: actively managing multiple sclerosis.

Hutchinson M.

Pract Neurol. 2009 Jun;9(3):133-43, discussion 144. doi: 10.1136/jnnp.2009.177212. Review.

PMID:
19448055
15.

A clinician's approach to modulate disease activity in MS.

Cook SD.

Rev Neurol Dis. 2005 Summer;2(3):117-23. Review.

PMID:
16400310
16.

[Immunomodulatory therapy in multiple sclerosis].

Csépány T, Bereczki D.

Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16. Review. Hungarian.

PMID:
15662768
17.

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.

Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.

Neurol Sci. 2005 Dec;26 Suppl 4:S174-8.

PMID:
16388353
18.

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.

Stuart WH.

Curr Med Res Opin. 2007 Jun;23(6):1199-208. Epub 2007 Apr 23. Review.

PMID:
17559719
19.

Early treatment of multiple sclerosis to prevent neurologic damage.

Coyle PK.

Neurology. 2008 Dec 9;71(24 Suppl 3):S3-7. doi: 10.1212/WNL.0b013e31818f3d6f.

PMID:
19064872
20.

Supplemental Content

Support Center